Alzheimer's disease research group (ADRG) by Scerri, Charles et al.
POSIT I ION PAPER 
CHARLES SCERRI' 
PETER FERRY' 
ANTHONY SCERRP 
RosenE FARRUGIA-BONELLQ4 
ANTHONY ZAHRA5 
DAVID MAMa' 
Alzheimer's disease research group (ADRG) 
Introduction 
In these last few years, there has 
been a growing consensus in Europe 
and beyond on the need of increasing 
research on neurodegenerative 
diseases including Alzheimer's 
disease and other related dementias. 
The societal impact and financial 
consequences of these diseases are 
already being felt and will continue 
to grow with the projected rise in the 
elderly population. Currently, there 
are over 35 million individuals with 
dementia worldwide, a figure that will 
treble by the year 2050. It has been 
estimated that formal and informal 
dementia care costs a total of €445 
billion (2009 data),' equivalent to 1 % 
of the global gross domestic product. 
It is therefore not surprising that the 
European Union supports various 
funding programmes in the hope of 
enhancing diagnosis, provide better 
treatment and improve care pathways 
and support for individuals with 
dementia, their caregivers and relatives. 
Alzheimer's disease 
Approximately 50% to 70% of all 
dementia cases are of the Alzheimer 
type. Alzheimer's disease, first 
identified in 1907 by the German 
neurologist Alois Alzheimer, is a 
progressive neurodegenerative disorder 
characterised by the presence of 
plaques and tangles in areas of the 
brain controlling cognitive function. 
Symptoms include memory impairment, 
difficulties in spatial orientation, 
changes in mood and personality, 
communication deficiencies and 
functional losses in activities of daily 
living. As the disease progresses, 
cognitive function becomes more 
impaired and individuals will eventually 
become totally dependent on others. 
Life expectancy following diagnosis 
varies but usually ranges between 8 
to 15 years. Risk factors include age, 
female gender, presence of Apo4 
gene, repeated head trauma and 
cardiovascular and metabolic factors. 
There is no single test to determine the 
presence of Alzheimer's disease and 
diagnosis relies on several features 
including the elimination of other 00-
morbidities, careful physical and mental 
examination, clinical investigation and 
disease progression. 
Dementia in Malta 
Particular interest in the field of 
dementia in Malta kicked off with the 
launch of the Malta Dementia Society 
in September 2004. The main aim 
of the society is that of increasing 
awareness on dementia in the Maltese 
islands through the organisation of 
seminars and talks on various aspects 
of dementia care and management. 
The Malta Dementia Society is an 
active member of Alzheimer Europe 
and Alzheimer Disease International 
and is frequently invited to participate 
in various European and pan-European 
initiatives. The first study to determine 
the prevalence of dementia in the 
Maltese islands was published in 2001.2 
The findings estimated that, in 2010, 
there would be approximately 4,500 
individuals with dementia, accounting 
to 1.1 % of the local population. This 
figure is expected to double in the next 
30 years. Recent data on prevalence 
rates using new criteria suggests that 
the number of individuals with dementia 
is higher than previously reportedand 
should exceed 14,000 cases by the 
year 2060.3 This progressive increase in 
affected individuals will have important 
socio-economic consequences and 
will invariably put greater demands on 
government-supported health care 
services. Moreover, there will be a 
growing burden on family members 
who, in the majority of cases, provide 
informal care at home.~ The importance 
of addressing this increasing 
phenomenon led to the setting-up of 
the Malta Dementia Strategy Group in 
2009 with the aim of presenting a series 
of recommendations to the Ministry of 
Health that should enhance high-quality 
dementia care.5 The final document 
laying down the backbone of the 
National Dementia Plan was presented 
in January of 2010. Although the final 
text have not been published to date, 
various recommendations included in 
the plan are being ratified such as the 
addition of dementia among the chronic 
conditions listed in the Schedule V of 
the Social Security Act. 
Dementia Research in Malta 
Although financial resources have 
been limited, research on dementia 
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including Alzheimer's disease in Malta 
has increased considerably in these 
last five years. Most of this research 
is based at the University of Malta 
and focuses on cellular, molecular, 
pharmacological and social aspects 
of dementia with special emphasis 
on Alzheimer's disease. Following a 
grant funded by the Malta Council of 
Science and Technology (Research 
and Innovation Programme 2008-
2012) to study how naturally occurring 
compounds can act as possible 
protective agents in Alzheimer's 
disease, a number of contributionswere 
published in international peer-
reviewed journals.~ Publications in 
other areas of Alzheimer's disease 
and related dementias include those 
by Innes et aJ,4 Scerri,s Scerri et al9 
and Scerri and Scerri. 1O A number of 
local and international undergraduate 
and graduate students have also been 
involved in the running of this research 
programme. 
Alzheimer's Disease Research 
Group (ADRG) 
The number of students interested 
in furthering their research in 
dementia is progressively increasing. 
Furthermore, Alzheimer's disease is 
becoming a topic of national interest 
and the number of research projects 
in which Malta is expected to act as 
a partner is expected to grow in the 
future. Albeit its size and geography, 
Malta can have an important voice as 
demostrated by the number of requests 
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to collaborate in various foreign-
based projects. With this in mind, the 
Department of Pathology has launched 
the Alzheimer's Disease Research 
Group with the aims of: 
1. Bringing together a number of 
multidisciplinary professionals in 
the field of Alzheimer's disease and 
related dementi as; 
2. Promoting and facilitating research 
and scientific collaboration in the 
diverse disciplines in Alzheimer's 
disease and related dementias 
with the ultimate goal of improving 
patient and caregiver care and 
quality of life; 
3. Acting in unision with local dementia 
NGOs in the dissemination 
of scientific knowledge and 
advancement of research goals in 
Alzheimer's disease and related 
dementias; 
4. Participating in and exploring local 
and international research funding 
proposals in the basic, social and 
clinical fields of Alzheimer's disease 
and related dementias. 
A number of international research 
institutions have already shown interest 
in forming workable partnershipswith 
this group both in national, European 
and pan-European funded projects. It 
is hoped that through such research 
cooperations, the University of Malta 
will continue on its endevour of 
becoming an important contributor 
in the field of Alzheimer's disease 
research. S 
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